WO2002055086A3 - Hormone replacement therapy method and its administration form - Google Patents

Hormone replacement therapy method and its administration form Download PDF

Info

Publication number
WO2002055086A3
WO2002055086A3 PCT/EP2002/000089 EP0200089W WO02055086A3 WO 2002055086 A3 WO2002055086 A3 WO 2002055086A3 EP 0200089 W EP0200089 W EP 0200089W WO 02055086 A3 WO02055086 A3 WO 02055086A3
Authority
WO
WIPO (PCT)
Prior art keywords
hormone
ingestion
replacement therapy
administration form
daily units
Prior art date
Application number
PCT/EP2002/000089
Other languages
French (fr)
Other versions
WO2002055086A2 (en
Inventor
Hermann Kulmann
Original Assignee
Schering Ag
Hermann Kulmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0206361-1A priority Critical patent/BR0206361A/en
Priority to EP02700196A priority patent/EP1372665B1/en
Priority to DE60216899T priority patent/DE60216899T2/en
Priority to MXPA03006157A priority patent/MXPA03006157A/en
Priority to US10/466,197 priority patent/US7871994B2/en
Priority to CA002433656A priority patent/CA2433656A1/en
Priority to DK02700196T priority patent/DK1372665T3/en
Priority to IL15665502A priority patent/IL156655A0/en
Application filed by Schering Ag, Hermann Kulmann filed Critical Schering Ag
Priority to JP2002555820A priority patent/JP2004525883A/en
Publication of WO2002055086A2 publication Critical patent/WO2002055086A2/en
Priority to NO20033155A priority patent/NO20033155L/en
Publication of WO2002055086A3 publication Critical patent/WO2002055086A3/en
Priority to CY20071100350T priority patent/CY1106374T1/en
Priority to AU2007202118A priority patent/AU2007202118A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Method for hormone replacement therapy, in which at least in the established postmenopause a daily unit with at least one hormonal component, namely with at least estrogen (E) and/or at least one gestagen (G) is administered permanently and continuously every day, characterized in that in at least one ingestion period preceding the permanent administration of hormone daily units is provided an ingestion pause (P), in which either no daily units or placebos or daily units with a much lower estrogen and/or gestagen content than during the permanent administration of hormone daily units in the established postmenopause and during the ingestion phase(s) of the preceding ingestion period are administered, as well as administration form for hormone therapy.
PCT/EP2002/000089 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form WO2002055086A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK02700196T DK1372665T3 (en) 2001-01-11 2002-01-08 Hormone replacement therapy and administration
DE60216899T DE60216899T2 (en) 2001-01-11 2002-01-08 HORMONE SUBSTITUTION THERAPY AND ITS PHARMACEUTICAL FORMS
MXPA03006157A MXPA03006157A (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form.
US10/466,197 US7871994B2 (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form
CA002433656A CA2433656A1 (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form
BR0206361-1A BR0206361A (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and method of administration
IL15665502A IL156655A0 (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form
EP02700196A EP1372665B1 (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form
JP2002555820A JP2004525883A (en) 2001-01-11 2002-01-08 Hormone replacement therapy methods and dosage forms
NO20033155A NO20033155L (en) 2001-01-11 2003-07-10 Method of hormone replacement therapy and its method of administration
CY20071100350T CY1106374T1 (en) 2001-01-11 2007-03-13 METHOD OF HORMONE REPLACEMENT THERAPY AND ITS ADMINISTRATION FORM
AU2007202118A AU2007202118A1 (en) 2001-01-11 2007-05-11 Hormone replacement therapy method and its administration form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10100911.9 2001-01-11
DE10100911A DE10100911A1 (en) 2001-01-11 2001-01-11 Process for hormone replacement therapy and its dosage form

Publications (2)

Publication Number Publication Date
WO2002055086A2 WO2002055086A2 (en) 2002-07-18
WO2002055086A3 true WO2002055086A3 (en) 2003-10-16

Family

ID=7670195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000089 WO2002055086A2 (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form

Country Status (21)

Country Link
US (1) US7871994B2 (en)
EP (1) EP1372665B1 (en)
JP (1) JP2004525883A (en)
AR (1) AR033413A1 (en)
AT (1) ATE348620T1 (en)
AU (1) AU2007202118A1 (en)
BR (1) BR0206361A (en)
CA (1) CA2433656A1 (en)
CY (1) CY1106374T1 (en)
DE (2) DE10100911A1 (en)
DK (1) DK1372665T3 (en)
ES (1) ES2278896T3 (en)
IL (1) IL156655A0 (en)
MX (1) MXPA03006157A (en)
NO (1) NO20033155L (en)
NZ (1) NZ539581A (en)
PE (1) PE20020795A1 (en)
PT (1) PT1372665E (en)
UY (1) UY27117A1 (en)
WO (1) WO2002055086A2 (en)
ZA (1) ZA200306120B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946198B2 (en) * 2002-08-28 2015-02-03 Robert Casper Estrogen replacement regimen
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
AU2003278434A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DK1670440T3 (en) 2003-09-29 2014-07-07 Novo Nordisk As HRT formulations
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980940A (en) * 1995-04-08 1999-11-09 Schering Ag Pharmaceutical combination preparation for hormonal contraception

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
DE4224534A1 (en) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
DE4405590C1 (en) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Postmenopausal hormone treatment
DE4405591C1 (en) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Postmenopausal hormone substitution
DE19539233A1 (en) 1995-10-21 1997-04-24 Klaus Dr Med Umbreit Two-phase oral contraception

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980940A (en) * 1995-04-08 1999-11-09 Schering Ag Pharmaceutical combination preparation for hormonal contraception

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTINDALE, 1993, PHARM. PRESS, LONDON, XP002229615 *

Also Published As

Publication number Publication date
JP2004525883A (en) 2004-08-26
MXPA03006157A (en) 2003-09-16
UY27117A1 (en) 2002-07-31
DE60216899D1 (en) 2007-02-01
DE60216899T2 (en) 2007-10-25
IL156655A0 (en) 2004-01-04
ES2278896T3 (en) 2007-08-16
US7871994B2 (en) 2011-01-18
CA2433656A1 (en) 2002-07-18
NO20033155L (en) 2003-09-10
AU2007202118A1 (en) 2007-05-31
PE20020795A1 (en) 2002-10-03
PT1372665E (en) 2007-03-30
WO2002055086A2 (en) 2002-07-18
US20040106586A1 (en) 2004-06-03
ZA200306120B (en) 2004-09-08
NZ539581A (en) 2007-07-27
NO20033155D0 (en) 2003-07-10
BR0206361A (en) 2004-02-17
EP1372665B1 (en) 2006-12-20
ATE348620T1 (en) 2007-01-15
EP1372665A2 (en) 2004-01-02
DE10100911A1 (en) 2002-08-01
AR033413A1 (en) 2003-12-17
DK1372665T3 (en) 2007-04-30
CY1106374T1 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
WO2001078701A3 (en) Method and compositions for preventing hormone induced adverse effects
WO1999012531A3 (en) Hormonal contraceptive
AU2002352334A1 (en) Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
HUP0401935A3 (en) Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
EP1418876A4 (en) Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
EP2153849A3 (en) Contraception process and administration form for the same
DE69710896D1 (en) Progestogen-anti-progestogen therapien
WO1998027929A3 (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
EP1000613A3 (en) Composition against the ageing and its use
WO1999004772A3 (en) Use of levobupivacaine
CA2368574A1 (en) Compositions for preventing and treating type i allergy
EP2275109A3 (en) Pregnane steroids for use in the treatment of CNS disorders
AU1569395A (en) Method for treatment of obesity using prolactin modulators and diet
WO2002055086A3 (en) Hormone replacement therapy method and its administration form
EP1340502A3 (en) Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
IL184257A0 (en) Solid peroral contraceptive drug
NO955084L (en) Estreno steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
WO2002081521A3 (en) Osteoprotegerin in milk
GB9718413D0 (en) Compositions
WO2003032961A3 (en) Methods for preventing and treating bone loss with steroid compounds
MXPA02004083A (en) Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same.
WO1999053064A3 (en) Methods of delivering glp-1
UA85003C2 (en) Solid peroral contraceptive drug
WO2003032909A3 (en) Methods of treating skin with diphosphonate derivatives
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 156655

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002700196

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2433656

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006157

Country of ref document: MX

Ref document number: 526927

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002555820

Country of ref document: JP

Ref document number: 2002233304

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/06120

Country of ref document: ZA

Ref document number: 200306120

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2002700196

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10466197

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002700196

Country of ref document: EP